IDCU HomeInfectious Diseases A-CD-GH-LM-QR-ST-ZHealthcare SafetyVaccine Preventable DiseasesIDCU Health TopicsDisease ReportingRelated Rules & RegulationsImmunization BranchAbout IDCURelated DSHS Sites
  • Contact Us

    TB and Hansen's Disease Branch

    MC 1939
    P.O. Box 149347
    Austin, TX 78756-9347

    Fax: 512-533-3167

    Email the TB Program

TB Control Standards



  1. Texas Tuberculosis Work Plan (PDF : 1,809 kB)
  2. TB Program Manual
  3. Standing Delegation Orders
  4. Policies and Procedures
  5. TXPHIN User Guide (PDF : 1,575 kB)

TB Program Manual
Title File Revised
DSHS Tuberculosis Standards for Texas Correctional and Detention Facilities PDF 605 kB 8/30/2018
Video-Based Directly Observed Therapy, Required and Recommended Activities PDF 277 kB 8/31/2018
  • Medication Layout for Video Enabled Directly Observed Therapy (VDOT)
PDF 147 kB 10/17/2017 
Binational Tuberculosis (TB) Program Manual PDF 505 kB 8/1/2017
Onsite Review PDF 472 kB  8/31/2018

Back to Top

Standing Delegation Orders FY 2020 
Title File Revised
Tuberculosis Clinical Services Provided by Authorized Licensed Nurses PDF 924 kB 9/1/2019
Tuberculosis Directly Observed Therapy (DOT) Services Provided by Authorized Staff PDF 359 kB 9/1/2019 
Tuberculosis Sputum Collection Services Provided by Authorized Staff PDF 370 kB 9/1/2019 
Tuberculosis Tuberculin Skin Testing (TST) Services Provided by Authorized Staff PDF 437 kB 9/1/2019
Tuberculosis Blood Specimen Collection Services Provided by Authorized Staff PDF 375 kB 9/1/2019

Back to Top

TB Policies and Procedures
Policy Name File Revised
5003 Standing Delegation Orders and Procedures for TB Prevention and Control PDF 26 kB 9/1/2013
TB-1002 Frequency of Tuberculin Skin Testing for Tuberculosis Infection for Adults in Various Settings PDF 60 kB 6/26/2008
TB-1003 Tuberculin Skin Testing Guidelines for Children in Various Settings PDF 77 kB 6/26/2008
TB-1004 Anergy Testing PDF 26 kB 6/26/2008
TB-4002 Drug Resistance PDF 141 kB 6/26/2008
TB-5001 Directly Observed Therapy for Active TB Disease and Latent TB Infection PDF 47 kB 6/26/2008
7000 Cohort Review Policy PDF 46 kB 3/9/2015
TB/HIV/STD Security Policies and Procedures

Back to Top

CDC Recommendations and Guidelines, by category

Current CDC publications for the prevention and control of TB organized by the following categories:

Control and Elimination These guidelines and recommendations address the obstacles and opportunities for controlling and eliminating TB in the United States, including the essential components of TB prevention and control programs, and the need to address TB in low-incidence areas of the United States and in communities with at-risk minority populations.
Diagnosis These diagnostic standards provide a practical guide and statement of principles for all persons involved in the care of patients with TB. They cover transmission of mycobacterium tuberculosis, clinical manifestations of TB, diagnostic microbiology, tuberculin skin test, definitions of TB disease and latent infection, and treatment of TB and TB infection.
HIV/AIDS These guidelines update previous CDC recommendations for the diagnosis, treatment, and prevention of TB among adults and children coinfected with HIV in the United States.
Infection Control Transmission of mycobacterium tuberculosis is a risk for patients and health care workers in healthcare facilities. These guidelines recommend strategies for reducing this risk in healthcare facilities.
Multidrug-Resistant TB (MDR) Outbreaks of multidrug-resistant TB (MDR) pose a public health problem and require rapid attention. These guidelines present an action plan to specifically address this problem and cover the management of persons exposed to MDR.
Testing Targeted tuberculin testing for latent tuberculosis infection (LTBI) is a strategic component of TB control that identifies persons at high risk for TB who would benefit by treatment of LTBI, if detected. These guidelines provide new recommendations for targeted tuberculin testing and treatment regimens for LTBI. Guidelines are also given to screening for TB and TB infection in high-risk populations.
Treatment These guidelines address treatment regimens for TB among adults, children, persons coinfected with HIV, persons exposed to MDR, and LTBI.
Vaccines These guidelines discuss the role of vaccines in TB prevention and control in the United States. Bacillus of Calmette and Guerin (BCG) is not recommended for programmatic use in the United States. Recognizing the importance of TB vaccines, the ACET recommends that public agencies and vaccine manufacturers develop a comprehensive strategy for new TB vaccine development.
All categories View a list of all categories for which the CDC has issued guidelines and recommendations for the prevention, treatment, and control of TB.

Back to Top

CDC TB Publications

Recommendations for Use of an Isoniazid–Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection
From CDC's MMWR Weekly; December 9, 2011 / 60(48);1650-1653

Updated Guidelines for Using Interferon Gamma Release Assays to Detect Mycobacterium tuberculosis Infection — United States, 2010
From CDC's MMWR Recommendations and Reports; June 25, 2010 / 59(RR05);1-25

Updated Guidelines for the Use of Nucleic Acid Amplification Tests in the Diagnosis of Tuberculosis
From CDC's MMWR Weekly; January 16, 2009 / 58(01);7-10

Plan to Combat Extensively Drug-Resistant Tuberculosis
From CDC's MMWR Recommendations and Reports; February 13, 2009; 58 (RR-03); 1-43

CDC Immigration Requirements: Technical Instructions for Tuberculosis Screening and Treatment (PDF)
From CDC

Prevention and Control of Tuberculosis in Correctional and Detention Facilities: Recommendations from CDC
From CDC’s MMWR Recommendations and Reports 2006; July 7, 2006 / Vol. 55 (RR09); 1-44

Guidelines for Using the QuantiFERON-TB Gold Test for Detecting Mycobacterium tuberculosis Infection, United States
From CDC's MMWR Recommendations and Reports; December 16, 2005; 54(No. RR-15): 49—55.

Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis
From Centers for Disease Control and Prevention's (CDC) MMWR Recommendations and Reports: December 16, 2005 / Vol. 54(RR15): 1-37

Controlling Tuberculosis in the United States – Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America
From CDC’s MMWR: November 4, 2005 / Vol. 54(RR12): 1-81

Guidelines for Preventing the Transmission of Mycobacterium tuberculosisin Health-Care Settings, 2005
From CDC’s MMWR Recommendations and Reports
, December 30, 2005 / Vol. 54 (RR17); 1-141

Slide Set — Guidelines for Preventing the Transmission of M. tuberculosis in Health-Care Settings, 2005

Guidelines for the Investigation of Contacts of Persons with Infectious Tuberculosis: Recommendations from the National Tuberculosis Controllers Association and CDC
From CDC’s MMWR Recommendations and Reports 2005; December 16, 2005 / Vol. 54 (RR15)/ 1-37

Treatment of Tuberculosis
American Thoracic Society, CDC, and Infectious Diseases Society of America
MMWR: June 20, 2003 / Vol. 52 (RR11): 1-77

Appendix B-Tuberculosis (TB) risk assessment worksheet )

TB Guidelines
From DTBE, a listing of all TB Guidelines issued from the division

Progressing Toward Tuberculosis Elimination in Low-Incidence Areas of the United States - Recommendations of the Advisory Council for the Elimination of Tuberculosis
From CDC’s MMWR Recommendations and Reports: May 3, 2002 / Vol. 51 (RR05);1-16

Diagnostic Standards/Classification of TB in Adults and Children (PDF)
American Journal of Respiratory Care and Critical Care Medicine, 2000; Vol. 161:1376-1395.

Back to Top

Last updated September 9, 2019